BridgeBio Pharma EBITDA 2018-2024 | BBIO
BridgeBio Pharma ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
BridgeBio Pharma Annual EBITDA
(Millions of US $) |
| 2023 |
$-601 |
| 2022 |
$-505 |
| 2021 |
$-571 |
| 2020 |
$-473 |
| 2019 |
$-265 |
| 2018 |
$-184 |
| 2017 |
$-44 |
BridgeBio Pharma Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$-174 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$-176 |
| 2023-09-30 |
$-156 |
| 2023-06-30 |
$-144 |
| 2023-03-31 |
$-125 |
| 2022-12-31 |
$-128 |
| 2022-09-30 |
$-127 |
| 2022-06-30 |
$-79 |
| 2022-03-31 |
$-172 |
| 2021-12-31 |
$-164 |
| 2021-09-30 |
$-149 |
| 2021-06-30 |
$-91 |
| 2021-03-31 |
$-167 |
| 2020-12-31 |
$-127 |
| 2020-09-30 |
$-121 |
| 2020-06-30 |
$-123 |
| 2020-03-31 |
$-102 |
| 2019-12-31 |
$-79 |
| 2019-09-30 |
$-55 |
| 2019-06-30 |
$-69 |
| 2019-03-31 |
$-64 |
| 2018-12-31 |
|
| 2018-09-30 |
$-41 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
